Kailera Therapeutics (NASDAQ:KLRA) Stock Falls 5.6% - Should You Sell?

Key Points

• KLRA shares fell 5.6% to $10.78, with trading volume down 86% versus the average session. The stock remains below its 50-day moving average of $15.93.
• Analyst sentiment is mixed but leans positive: MarketBeat reports a “Moderate Buy” consensus and a $42.75 target price, while Weiss Ratings initiated coverage with a “Sell” rating.
• Kailera reported a quarterly loss of $1.09 per share, missing estimates by $0.35, and analysts expect a full-year loss of $3.89 per share. Several institutional investors recently established positions, including Wellington Management and Frazier Life Sciences.

Shares of Kailera Therapeutics, Inc. (NASDAQ:KLRA - Get Free Report) fell 5.6% during trading on Thursday. The stock traded as low as $10.69 and last traded at $10.78. 113,294 shares changed hands during trading, a decline of 86% from the average session volume of 806,460 shares. The stock had previously closed at $11.42.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings began coverage on shares of Kailera Therapeutics in a research note on Friday, August 14th. They issued a "sell (d)" rating for the company. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Kailera Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $42.75.

Kailera Therapeutics Price Performance

The company's 50 day simple moving average is $15.93. The firm has a market capitalization of $1.44 billion and a PE ratio of -0.00.

Kailera Therapeutics (NASDAQ:KLRA - Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.35). Research analysts expect that Kailera Therapeutics, Inc. will post -3.89 EPS for the current year.

Institutional Investors Weigh In On Kailera Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of KLRA. Tidal Investments LLC bought a new position in shares of Kailera Therapeutics in the second quarter valued at approximately $309,000. Squarepoint Ops LLC bought a new stake in Kailera Therapeutics during the second quarter worth $993,000. State Street Corp bought a new stake in Kailera Therapeutics during the second quarter worth $19,126,000. Frazier Life Sciences Management L.P. purchased a new position in Kailera Therapeutics in the second quarter worth $24,233,000. Finally, Wellington Management Group LLP purchased a new position in Kailera Therapeutics in the second quarter worth $64,308,000.

Kailera Therapeutics Company Profile

Kailera Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for obesity and related metabolic diseases. The company's programs are designed to address the substantial medical needs associated with excess weight and metabolic disorders.

Kailera's lead product candidate is KAIL-001, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist intended for the treatment of obesity and potentially related conditions. The company is advancing its pipeline through clinical development and regulatory activities, although its products remain investigational and are not yet approved for commercial use.

The company's operations are centered on the development of therapies for global markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.